Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

SCIENCE

The Claim

In humans, the GIP gene functions as an oncogene in ovarian tumors.

Verified by Lenz ·

The Short Version

The claim is not supported because it confuses two different genes. The ovarian cancer “gip2” literature refers to GNAI2, not the human GIP gene that encodes an incretin hormone. Studies about incretin drugs or indirect pathway effects also do not show that GIP itself functions as an oncogene in ovarian tumors.

Caveats

  • Do not confuse GIP with “gip2”/GNAI2; they are distinct genes with different functions and cancer relevance.
  • Drug-pathway studies involving GIP or GLP-1 agonists are not proof that the GIP gene is an oncogene, especially when the data are indirect or from non-ovarian models.
  • Advocacy websites and AI-generated background material are not reliable authorities for gene-function classification.

The Receipts

  1. Determinant role for the gep oncogenes, Gα12/13, in ovarian cancer

    PMC

  2. The Role of Endocrine G Protein-Coupled Receptors in Ovarian Neoplasms

    PMC

  3. GNAi2/gip2-Regulated Transcriptome and Its Therapeutic Implications in Ovarian Cancer

    PubMed

  4. GNAI2 guanine nucleotide binding protein G(i) subunit alpha 2 [Homo sapiens (human)]

    NCBI Gene

  5. Glucagon-like peptide 1 receptor agonists and cancer risk

    NIH PubMed Central

  6. The gynecologic tumor risk related to GLP-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors

    NIH PubMed Central

  7. GNAI2: A Novel Tumor Suppressor in Ovarian Cancer?

    PMC

  8. Association between glucagon-like peptide-1 receptor agonists and ovarian cancer outcomes

    PubMed (NIH)

  9. The oncogenic roles of GPR176 in ovarian cancer

    PubMed

  10. Galpha(i2), a Metastasis Associated G Protein

    PubMed

+ 11 more sources — see the full list on Lenz

Filed Under

GIP GeneHomo sapiensOvarian Tumors

More Fact Checks